KEI Comments Regarding NIH Exclusive License to RNAceuticals for Anti-HIV Antibodies

On July 27, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV… Continue Reading

KEI Comments on NIH Exclusive License to Kriya Therapeutics for Diabetes and Obesity Treatment

On Tuesday April 28, 2020, KEI submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: AAV Mediated Exendin-4 Gene Transfer to Salivary Glands To Protect Subjects From Diabetes or Obesity” (85… Continue Reading

WHO Director-General Remarks in support of global pooling of rights in COVID-19 Technologies and data, in open science and open data

On April 6, 2020, the Director-General of the World Health Organization (WHO), Dr. Tedros Ghebreyesus, gave a media briefing on COVID-19 and the WHO’s efforts to combat the pandemic. In his remarks, Dr. Tedros specifically highlighted the proposal by the… Continue Reading

FDA States Submission Date of Gilead’s Coronavirus Treatment Orphan Status Application is ‘Confidential’

On Monday March 23, 2020, Gilead Sciences’ remdesivir received orphan designation from the US Food and Drug Administration (FDA) for the treatment of COVID-19. Remdesivir has been reported to be one of the candidates to potentially treat COVID-19, which the… Continue Reading

KEI Requests the NIH to Investigate Failure to Disclose Federal Funding in Opdivo and Keytruda Patents

On December 20, 2019, Knowledge Ecology International (KEI) filed a request to the National Institutes of Health (NIH) that it investigate an apparent failure to disclose federal funding in patents associated with cancer immunotherapies Opdivo and Keytruda. A court case… Continue Reading

KEI, UACT, Public Citizen, SSW, LWC Health Appeal NIH Grant of Exclusive License on Gene Therapy for Cancer to Intima Biosciences

On October 26, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Public Citizen, Social Security Works (SSW), LWC Health, Ruth Lopert, Manon Ress, and Terry Love filed an administrative appeal with the National Institutes of Health (NIH).… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License on GPC3-Expressing Cancer Treatment

On Tuesday November 12, 2019, KEI and the Union for Affordable Cancer Treatment (UACT) filed comments on the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: The Development of an Anti-GPC3 Radionuclide Immunoconjugate for the Treatment… Continue Reading

KEI Comments to the NIH on Exclusive License to Opsis Therapeutics for Retinal Cell Therapies

On October 18, 2019, Knowledge Ecology International (KEI) submitted comments to the Federal Register Notice for the “Prospective Grant of an Exclusive Patent License: Compositions, Devices and Processes for Production and Delivery of Cell Grafts of Manufactured Retinal Pigment Epithelium… Continue Reading

KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology

(Update: The NIH provided a response to our comments on November 15, 2019) On Friday October 18, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments on the “Prospective Grant of an Exclusive Patent License:… Continue Reading